PITTSBURGH, May 22, 2023
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global
healthcare company, today announced that as part of its ongoing
board refreshment efforts, Leo
Groothuis has been appointed as Viatris' newest member of
its board of directors. Groothuis fills the vacancy created by the
previous departure of Michael
Goettler in April of this year.
Groothuis has significant international experience and serves as
General Counsel of HAL Investments, the Dutch investment subsidiary
of HAL Holding N.V., an international investment company listed on
the Amsterdam stock exchange,
which is focused on increasing shareholder value. In addition to
his strategic, financial and governance focus, he has also been
actively involved in the development and execution of HAL
Investments' ESG strategy.
Throughout his career, Groothuis has been a trusted C-suite and
board advisor to some of the largest companies in both Europe and the U.S. Prior to his role at HAL
Investments, he served as practice leader at NautaDutilh, an
international law firm, where he guided numerous multi-national
companies on significant and complex transactions. As a result, he
is recognized as a top lawyer and thought leader in corporate
governance, capital markets and M&A.
Viatris Executive Chairman Robert J.
Coury said, "We are extremely pleased to welcome
Leo Groothuis, a recognized top
international executive to the Viatris board. We believe his proven
strategic, corporate governance and capital markets experience
should serve as a tremendous asset for Viatris, as we continue to
look for ways to build and unlock value for our shareholders."
About Viatris
Viatris Inc. (NASDAQ: VTRS) is
a global healthcare company empowering people worldwide to live
healthier at every stage of life. We provide access to medicines,
advance sustainable operations, develop innovative solutions and
leverage our collective expertise to connect more people to more
products and services through our one-of-a-kind Global Healthcare
Gateway®. Formed in November 2020,
Viatris brings together scientific, manufacturing and distribution
expertise with proven regulatory, medical, and commercial
capabilities to deliver high-quality medicines to patients in more
than 165 countries and territories. Viatris' portfolio comprises
more than 1,400 approved molecules across a wide range of
therapeutic areas, spanning both non-communicable and infectious
diseases, including globally recognized brands, complex generic and
branded medicines and a variety of over-the-counter consumer
products. With more than 38,000 colleagues globally, Viatris is
headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com
and investor.viatris.com, and connect with us on Twitter, LinkedIn,
Instagram and YouTube.
Forward-looking Statements
This press release includes statements that constitute
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward looking statements may include
statements that we believe his proven strategic, corporate
governance and capital markets experience should serve as a
tremendous asset for Viatris, as we continue to look for ways to
build and unlock value for our shareholders. Factors that could
cause or contribute to such differences include, but are not
limited to: the possibility that the Company may be unable to
realize the intended benefits of, or achieve the intended goals or
outlooks with respect to, its strategic initiatives; the
possibility that the Company may be unable to achieve expected
benefits, synergies and operating efficiencies in connection with
acquisitions, divestitures, or its global restructuring program,
within the expected timeframe or at all; impairment charges or
other losses related to the divestiture or sale of businesses or
assets; the Company's failure to achieve expected or targeted
future financial and operating performance and results; the
potential impact of public health outbreaks, epidemics and
pandemics, including the ongoing challenges and uncertainties posed
by COVID-19; actions and decisions of healthcare and pharmaceutical
regulators; changes in healthcare and pharmaceutical laws and
regulations in the U.S. and abroad; any regulatory, legal or other
impediments to Viatris' ability to bring new products to market,
including but not limited to "at-risk" launches; Viatris' or its
partners' ability to develop, manufacture, and commercialize
products; the scope, timing and outcome of any ongoing legal
proceedings, and the impact of any such proceedings; any
significant breach of data security or data privacy or disruptions
to our information technology systems; risks associated with
international operations; the ability to protect intellectual
property and preserve intellectual property rights; changes in
third-party relationships; the effect of any changes in Viatris' or
its partners' customer and supplier relationships and customer
purchasing patterns; the impacts of competition; changes in the
economic and financial conditions of Viatris or its partners;
uncertainties and matters beyond the control of management,
including general economic conditions, inflation and exchange
rates; failure to execute stock repurchases consistent with current
expectations; stock price volatility; and the other risks described
in Viatris' filings with the Securities and Exchange Commission
(SEC). Viatris routinely uses its website as a means of disclosing
material information to the public in a broad, non-exclusionary
manner for purposes of the SEC's Regulation Fair Disclosure (Reg
FD). Viatris undertakes no obligation to update these statements
for revisions or changes after the date of this release other than
as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-leo-groothuis-to-companys-board-of-directors-301830418.html
SOURCE Viatris Inc.